Proposes $1 billion rewards for new drugs in January 2018 CMS collaboration signed, raising additional £3.0 million in equity in December 2017 Fast Track in USA status under QIDP awarded to XF-73 in March 2018 G20 Declaration on Combating Antimicrobial Resistance (“AMR”) in July 2017 IPO September 2017 Equity funding at IPO raising £15.3 million USA IND for XF-73 opened in February 2018 microbiological testing confirms XF-73 efficacy in standard models and action against some new resistant strains Highlights Destiny Pharma is focused and well funded Financial statements Governance Strategic report Destiny Pharma plc Annual Report and Financial Statements 2017 01 The successful IPO in September 2017 means that Destiny Pharma plc is now well placed to develop its novel drug pipeline.